TTY Biopharm Company Limited

TPEX:4105 Stock Report

Market Cap: NT$19.2b

TTY Biopharm Valuation

Is 4105 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4105 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4105 (NT$77.1) is trading below our estimate of fair value (NT$92.52)

Significantly Below Fair Value: 4105 is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4105?

Other financial metrics that can be useful for relative valuation.

4105 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA12x
PEG Ratio0.9x

Price to Earnings Ratio vs Peers

How does 4105's PE Ratio compare to its peers?

The above table shows the PE ratio for 4105 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average53.4x
1789 ScinoPharm Taiwan
79.1xn/aNT$22.7b
4746 Formosa Laboratories
96.2xn/aNT$12.1b
4114 Synmosa Biopharma
24.8xn/aNT$14.7b
1720 Standard Chemical & Pharmaceutical
13.5xn/aNT$11.3b
4105 TTY Biopharm
17x18.7%NT$19.2b

Price-To-Earnings vs Peers: 4105 is good value based on its Price-To-Earnings Ratio (17x) compared to the peer average (53.4x).

Price to Earnings Ratio vs Industry

How does 4105's PE Ratio compare vs other companies in the TW Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.1%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.1%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: 4105 is good value based on its Price-To-Earnings Ratio (17x) compared to the TW Pharmaceuticals industry average (25.5x).

Price to Earnings Ratio vs Fair Ratio

What is 4105's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4105 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17x
Fair PE Ratio18x

Price-To-Earnings vs Fair Ratio: 4105 is good value based on its Price-To-Earnings Ratio (17x) compared to the estimated Fair Price-To-Earnings Ratio (18x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4105 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNT$77.10
NT$86.50
+12.2%
9.8%NT$95.00NT$78.00n/a2
Apr ’25NT$78.40
NT$86.50
+10.3%
9.8%NT$95.00NT$78.00n/a2
Mar ’25NT$80.80
NT$86.50
+7.1%
9.8%NT$95.00NT$78.00n/a2
Feb ’25NT$78.40
NT$86.50
+10.3%
9.8%NT$95.00NT$78.00n/a2
Jan ’25NT$80.40
NT$86.00
+7.0%
10.5%NT$95.00NT$77.00n/a2
Dec ’24NT$83.10
NT$86.00
+3.5%
10.5%NT$95.00NT$77.00n/a2
Nov ’24NT$84.50
NT$86.00
+1.8%
10.5%NT$95.00NT$77.00n/a2
Sep ’24NT$76.60
NT$85.00
+11.0%
9.4%NT$93.00NT$77.00n/a2
Aug ’24NT$76.40
NT$85.00
+11.3%
9.4%NT$93.00NT$77.00n/a2
Jul ’24NT$78.40
NT$84.50
+7.8%
10.1%NT$93.00NT$76.00n/a2
Jun ’24NT$75.00
NT$78.00
+4.0%
2.6%NT$80.00NT$76.00n/a2
May ’24NT$76.90
NT$78.00
+1.4%
2.6%NT$80.00NT$76.00NT$77.102
Apr ’24NT$76.20
NT$74.00
-2.9%
8.1%NT$80.00NT$68.00NT$78.402
Mar ’24NT$77.90
NT$71.50
-8.2%
4.9%NT$75.00NT$68.00NT$80.802
Feb ’24NT$77.40
NT$71.50
-7.6%
4.9%NT$75.00NT$68.00NT$78.402
Jan ’24NT$83.40
NT$79.50
-4.7%
5.7%NT$84.00NT$75.00NT$80.402
Dec ’23NT$78.50
NT$79.50
+1.3%
5.7%NT$84.00NT$75.00NT$83.102
Nov ’23NT$74.90
NT$76.50
+2.1%
2.0%NT$78.00NT$75.00NT$84.502
Oct ’23NT$72.70
NT$76.50
+5.2%
2.0%NT$78.00NT$75.00NT$77.202
Sep ’23NT$75.20
NT$73.00
-2.9%
6.8%NT$78.00NT$68.00NT$76.602
Aug ’23NT$70.90
NT$73.00
+3.0%
6.8%NT$78.00NT$68.00NT$76.402
Jul ’23NT$71.10
NT$73.00
+2.7%
9.6%NT$85.00NT$68.00NT$78.404
Jun ’23NT$69.00
NT$73.00
+5.8%
9.6%NT$85.00NT$68.00NT$75.004
May ’23NT$74.70
NT$73.00
-2.3%
9.6%NT$85.00NT$68.00NT$76.904

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.